Frailty Predicts Higher In-Hospital Mortality After Radical Cystectomy
Frail patients are more likely than non-frail patients to experience adverse perioperative outcomes after radical cystectomy, a study found.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
RCC Ablation Technique Influences Survival Time
One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Sunitinib Timing for mRCC Does Not Affect CN Complication Rates
Investigators observed no differences in surgery time, blood loss, and hospital stay, with deferred vs upfront cytoreductive nephrectomy.
Poor Diabetes Control Linked to Worse NMIBC Outcomes
Among patients with non-muscle-invasive bladder cancer, those with diabetes and HbA1c levels below 7% have shorter progression-free survival.
Partial Nephrectomy Preferable for T1a RCC
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
PN, RN Offer Comparable Long-Term Survival for T1b RCC
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Targeted RCC Therapies Benefit ‘Real World’ Medicare Patients
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCC
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Earlier Pembrolizumab Use May Be Beneficial in mUC
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
Adverse Events Associated With Outcomes in PD-1/PD-L1–Treated Urothelial Carcinoma
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
Nivolumab and Ipilimumab Combo Shows Promise in Advanced RCC With Brain Metastases
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Enfortumab Vedotin Yields High Response Rate in Advanced Urothelial Cancer
The investigators said the data justify and support the submission of enfortumab vedotin for consideration under FDA’s accelerated approval pathway.
Inactivating Mutations in Genes Encoding for Components of the mSWI/SNF Complex May Be Associated With Improved OS in Immunotherapy-Treated Patients
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.
Incidence Rates for Aggressive Uterine Cancers on the Rise
Hysterectomy-corrected uterine cancer incidence rates show that nonendometrioid carcinoma rates have been increasing among all women.
Rise in TSH: A Prognostic Indicator in Sunitinib-Treated Metastatic RCC?
In this study, more than 40% of patients with metastatic RCC showed signs of hypothyroidism following 2 weeks of treatment with sunitinib.
Checkpoint Inhibitor-Based Combination Prolonged Progression in RCC
No overall survival benefit has yet been seen with the regimen in RCC.
Quitting Smoking Lowers Risk for Bladder Cancer Postmenopause
Among postmenopausal women, former smokers have a reduced risk for bladder cancer within the first 10 years of cessation.
Percutaneous Ablation Appropriate for Localized Renal Tumors
Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
Want to read more?
Please login or register first to view this content.
